Lipid-Based Formulations for Therapy of Vector-Borne Protozoan Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: closed (10 May 2023) | Viewed by 5043

Special Issue Editor


E-Mail Website
Guest Editor
Department Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Minas Gerais, Brazil
Interests: drug delivery systems; liposomes; drug targeting; oral delivery; leishmaniasis; antiparasitic chemotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Vector-borne protozoan diseases represent a serious public health problem, especially in the tropics where poverty, together with vector-favorable climates, prevails. Diseases caused by Plasmodia (malaria), and three major trypanosomatid diseases (leishmaniasis, African Human Trypanosomiasis (HAT) and Chagas disease) are among the most prevalent and severe human vector-borne protozoan infections. Unfortunately, the sector of drug research has attracted less attention for these diseases, despite their heavy burden. Consequently, only a limited number of pharmaceuticals are currently in use. Furthermore, treatments are limited by the low efficacy and high toxicity of existing drugs, resulting in frequent treatment failure, low patient compliance and the emergence of drug resistance. Thus, there is urgent need for new more effective drugs and therapeutic strategies for these diseases.

The improvement of drugs that are already established in clinics through innovative drug delivery systems is an effective strategy for fast drug development. Delivery systems allow the modulation of drug solubilization or aggregation state, its protection from degradation and the control of pharmacokinetic parameters such as drug bioavailability, half-life, and biodistribution, resulting ultimately in enhanced drug efficacy and reduced drug toxicity.

Delivery systems with a nanometric dimension have been especially successful in allowing precise drug targeting of infectious sites. Among nanosystems, those containing lipids (e.g., liposomes, nanostructured lipid carriers, micelles, nano- and microemulsions, and solid lipid nanoparticles) have enormous potential in the field of drug delivery due to their unique biocompatibility and their structural and functional versatilities.

This Special Issue seeks to present a collection of innovative studies describing recent advances in the development of lipid-based drug formulations to improve the therapy of vector-borne protozoan infections. Special attention is given to works that explore alternative administration routes, immunochemotherapy strategies and address major challenges in current drug development, such as drug delivery across biological barriers, effective drug targeting, as well as the formulation of large molecules (e.g., proteins and nucleic acids).

Prof. Dr. Frédéric Frézard
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liposomes
  • lipid-based formulations
  • solid lipid nanoparticles
  • micelles
  • oral drug delivery
  • drug targeting
  • protozoan diseases
  • leishmaniasis
  • Chagas disease
  • malaria

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 2278 KiB  
Article
Nanoassemblies from Amphiphilic Sb Complexes Target Infection Sites in Models of Visceral and Cutaneous Leishmaniases
by Juliane S. Lanza, Virginia M. R. Vallejos, Guilherme S. Ramos, Ana Carolina B. de Oliveira, Cynthia Demicheli, Luis Rivas, Sébastien Pomel, Philippe M. Loiseau and Frédéric Frézard
Pharmaceutics 2022, 14(8), 1743; https://doi.org/10.3390/pharmaceutics14081743 - 21 Aug 2022
Cited by 1 | Viewed by 1492
Abstract
This work aims to evaluate whether nanoassemblies (NanoSb) made from antimony(V) complexes with octanoyl-N-methylglucamide (SbL8) or decanoyl-N-methylglucamide (SbL10) would effectively target the infection sites in visceral and cutaneous leishmaniases (VL and CL). NanoSb were investigated regarding stability at different [...] Read more.
This work aims to evaluate whether nanoassemblies (NanoSb) made from antimony(V) complexes with octanoyl-N-methylglucamide (SbL8) or decanoyl-N-methylglucamide (SbL10) would effectively target the infection sites in visceral and cutaneous leishmaniases (VL and CL). NanoSb were investigated regarding stability at different pHs, accumulation of Sb in the macrophage host cell and liver, and in vitro and in vivo activities in models of leishmaniasis. The kinetic stability assay showed that NanoSb are stable at neutral pH, but release incorporated lipophilic substance after conformational change in media that mimic the gastric fluid and the parasitophorous vacuole. NanoSb promoted greater accumulation of Sb in macrophages and in the liver of mice after parenteral administration, when compared to conventional antimonial Glucantime®. SbL10 was much more active than Glucantime® against intramacrophage Leishmania amastigotes and less cytotoxic than SbL8 against macrophages. The in vitro SbL10 activity was further enhanced with co-incorporated miltefosine. NanoSb showed high antileishmanial activity in the L. donovani murine VL after parenteral administration and moderate activity in the L. amazonensis murine CL after topical treatment. This study supports the ability of NanoSb to effectively deliver a combination of Sb and co-incorporated drug to host cell and infected tissues, in a better way than Glucantime® does. Full article
Show Figures

Graphical abstract

Review

Jump to: Research

24 pages, 2984 KiB  
Review
Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations
by Frédéric Frézard, Marta M. G. Aguiar, Lucas A. M. Ferreira, Guilherme S. Ramos, Thais T. Santos, Gabriel S. M. Borges, Virgínia M. R. Vallejos and Helane L. O. De Morais
Pharmaceutics 2023, 15(1), 99; https://doi.org/10.3390/pharmaceutics15010099 - 28 Dec 2022
Cited by 14 | Viewed by 3113
Abstract
The liposomal amphotericin B (AmB) formulation, AmBisome®, still represents the best therapeutic option for cutaneous and visceral leishmaniasis. However, its clinical efficacy depends on the patient’s immunological status, the clinical manifestation and the endemic region. Moreover, the need for parenteral administration, [...] Read more.
The liposomal amphotericin B (AmB) formulation, AmBisome®, still represents the best therapeutic option for cutaneous and visceral leishmaniasis. However, its clinical efficacy depends on the patient’s immunological status, the clinical manifestation and the endemic region. Moreover, the need for parenteral administration, its side effects and high cost significantly limit its use in developing countries. This review reports the progress achieved thus far toward the understanding of the mechanism responsible for the reduced toxicity of liposomal AmB formulations and the factors that influence their efficacy against leishmaniasis. It also presents the recent advances in the development of more effective liposomal AmB formulations, including topical and oral liposome formulations. The critical role of the AmB aggregation state and release rate in the reduction of drug toxicity and in the drug efficacy by non-invasive routes is emphasized. This paper is expected to guide future research and development of innovative liposomal formulations of AmB. Full article
Show Figures

Graphical abstract

Back to TopTop